KPLH1130
Based on 2 publication(s) in Google Scholar
KPLH1130 is a pyruvate dehydrogenase kinase (PDK) inhibitor. KPLH1130 potently inhibits M1 macrophage polarization by reducing the expression of pro-inflammatory cytokines, decreasing the levels of M1 phenotype markers (HIF-1α, iNOS) and nitric oxide (NO) production. KPLH1130 prevents the reduction of mitochondrial oxygen consumption rate (OCR) induced by inflammatory stimuli (LPS ((HY-D1056) + IFN-γ) in various macrophage types. KPLH1130 improves glucose tolerance in HFD-fed mice. KPLH1130 can be used for the study of obesity-associated metabolic disorders and other inflammatory conditions.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.86%
- CAS No.: 906669-07-6
- Formule: C15H13N3O3
- Masse moléculaire:283.28
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Aging Compound Library
HY-L034
-
Differentiation Inducing Compound Library
HY-L038
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Glycolysis Compound Library
HY-L058
-
Glutamine Metabolism Compound Library
HY-L064
-
Neuroprotective Compound Library
HY-L070
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Angiogenesis-Related Compound Library
HY-L088
-
Mitochondria-Targeted Compound Library
HY-L089
-
Transcription Factor-Targeted Library
HY-L090
-
Glucose Metabolism Compound Library
HY-L092
-
Targeted Diversity Library
HY-L099
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
TCA Cycle Compound Library
HY-L148
-
Membrane Protein-targeted Compound Library
HY-L149
-
Cytokine Inhibitors Library
HY-L161
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Macrophage Related Compound Library
HY-L174
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) KPLH1130
More
Activité biologique
PDK[1]
KPLH1130 (1-10 μM, 12 h) significantly reduces the mRNA expression of pro-inflammatory cytokines (TNFα, IL-6, IL-1) and the secretion of corresponding pro-inflammatory effectors in in Zymosan (HY-159069)-elicited peritoneal macrophages (ZEPMs) and LPS-elicited peritoneal macrophages (LEPMs) stimulated with LPS (HY-D1056) + IFN-γ[1].
KPLH1130 (1-10 μM, 12 h) notably decreases the protein levels of M1 macrophage markers (HIF-1α, iNOS) and the production of nitric oxide (NO) in LPS + IFN-γ-stimulated PMs[1].
KPLH1130 (10 μM, 3 h) prevents the reduction of basal and maximal oxygen consumption rate (OCR) in bone marrow-derived macrophages (BMDMs) induced by M1 polarization (LPS 100 ng/mL + IFN-γ 10 ng/mL), improving mitochondrial respiration function[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Zymosan-elicited peritoneal macrophages (ZEPMs) and LPS-elicited peritoneal macrophages (LEPMs) stimulated with LPS (HY-D1056) + IFN-γ
-
Concentration:1, 5, 10 μM
-
Incubation Time:12 h
-
Result:Reduced the mRNA expression of pro-inflammatory cytokines (TNFα, IL-6, IL-1) and the secretion of corresponding pro-inflammatory effectors.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 906669-07-6
-
Appearance Solid
-
Masse moléculaire 283.28
-
Formule C15H13N3O3
-
Color Off-white to gray
-
SMILES
OC1=CC=C(C2=NNC(N2C3=CC=C(C)C=C3)=O)C(O)=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Poult Sci
ROS-mediated M1 polarization-necroptosis crosstalk involved in Di-(2-ethylhexyl) phthalate-induced chicken liver injury. [Abstract]2025 Jan;104(1):104558. PMID: 39631278 -
Biol Pharm Bull
Chronic Corticosterone Treatment Decreases Extracellular pH and Increases Lactate Release via PDK4 Upregulation in Cultured Astrocytes. [Abstract]2024;47(9):1542-1549. PMID: 39313390
Solvant et solubilité
DMSO : 135 mg/mL (476.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.25 mg/mL (7.94 mM); Clear solution
This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (282 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5301 mL | 17.6504 mL | 35.3008 mL | 88.2519 mL |
| 5 mM | 0.7060 mL | 3.5301 mL | 7.0602 mL | 17.6504 mL | |
| 10 mM | 0.3530 mL | 1.7650 mL | 3.5301 mL | 8.8252 mL | |
| 15 mM | 0.2353 mL | 1.1767 mL | 2.3534 mL | 5.8835 mL | |
| 20 mM | 0.1765 mL | 0.8825 mL | 1.7650 mL | 4.4126 mL | |
| 25 mM | 0.1412 mL | 0.7060 mL | 1.4120 mL | 3.5301 mL | |
| 30 mM | 0.1177 mL | 0.5883 mL | 1.1767 mL | 2.9417 mL | |
| 40 mM | 0.0883 mL | 0.4413 mL | 0.8825 mL | 2.2063 mL | |
| 50 mM | 0.0706 mL | 0.3530 mL | 0.7060 mL | 1.7650 mL | |
| 60 mM | 0.0588 mL | 0.2942 mL | 0.5883 mL | 1.4709 mL | |
| 80 mM | 0.0441 mL | 0.2206 mL | 0.4413 mL | 1.1031 mL | |
| 100 mM | 0.0353 mL | 0.1765 mL | 0.3530 mL | 0.8825 mL |
KPLH1130 Related Classifications
HY-128578 Related Classifications
Powered by Bioz